RET and medullary thyroid gland carcinoma: Selpercatinib is a more effective treatment compared to platinum-based chemotherapy plus ICIs or docetaxel in patients with RET fusion-positive aNSCLC, or cabozantinib/vandetanib in patients with RET-mutated MTC, as demonstrated by the results from clinical studies [10,11,12].